Your browser doesn't support javascript.
loading
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang, Zefei; Li, Wei; Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Cui, Shude; Wang, Shusen; Ouyang, Quchang; Yin, Yongmei; Geng, Cuizhi; Tong, Zhongsheng; Cheng, Ying; Pan, Yueyin; Sun, Yuping; Wang, Hong; Ouyang, Tao; Gu, Kangsheng; Feng, Jifeng; Wang, Xiaojia; Wang, Shubin; Liu, Tianshu; Gao, Jinghua; Cristofanilli, Massimo; Ning, Zhiqiang; Lu, Xianping.
  • Jiang Z; The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China. Electronic address: jiangzefei@csco.org.cn.
  • Li W; The First Hospital of Jilin University, Changchun, China.
  • Hu X; Fudan University Shanghai Cancer Centre, Shanghai, China.
  • Zhang Q; Harbin Medical University Cancer Hospital, Harbin, China.
  • Sun T; Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Cui S; Henan Cancer Hospital, Zhengzhou, China.
  • Wang S; Sun Yat-Sen University Cancer Centre, Guangzhou, China.
  • Ouyang Q; Hunan Cancer Hospital, Changsha, China.
  • Yin Y; Jiangsu Province Hospital, Nanjing, China.
  • Geng C; Tumour Hospital of Hebei Province, Shijiazhuang, China.
  • Tong Z; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Cheng Y; Jilin Cancer Hospital, Changchun, China.
  • Pan Y; Anhui Provincial Hospital, Hefei, China.
  • Sun Y; Jinan Central Hospital, Jinan, China.
  • Wang H; The Third Hospital of Nanchang, Nanchang, China.
  • Ouyang T; Beijing Cancer Hospital, Beijing, China.
  • Gu K; The First Affiliated Hospital of Anui Medical University, Hefei, China.
  • Feng J; Jiangsu Cancer Hospital, Nanjing, China.
  • Wang X; Zhejiang Cancer Hospital, Hangzhou, China.
  • Wang S; Beijing University Shenzhen Hospital, Shenzhen, China.
  • Liu T; Fudan University Zhongshan Hospital, Shanghai, China.
  • Gao J; Cangzhou Central Hospital, Cangzhou, China.
  • Cristofanilli M; Feinberg School of Medicine, Chicago, IL, USA.
  • Ning Z; Chipscreen Biosciences, Shenzhen, China.
  • Lu X; Chipscreen Biosciences, Shenzhen, China.
Lancet Oncol ; 20(6): 806-815, 2019 06.
Article en En | MEDLINE | ID: mdl-31036468
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Recuperativa / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Año: 2019 Tipo del documento: Article